Reduction of [(18)F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma

Mol Imaging Biol. 2011 Apr;13(2):227-31. doi: 10.1007/s11307-010-0365-2.

Abstract

Purpose: The purpose of this study was to investigate the changes of tumor hypoxia as a result of neoadjuvant chemotherapy (NAC) by measuring the changes of [(18)F]fluoromisonidazole ([(18)F]FMISO) positron emission tomography (PET) uptake, as well as to look into the ability of [(18)F]FMISO PET to predict the NAC result.

Procedures: A total of 13 patients with locally advanced head and neck squamous cell carcinoma underwent [(18)F]FMISO PET scans before and after NAC. For analysis of PET index, maximum standardized uptake value, tumor-to-muscle ratio, and hypoxic volume (HV) were measured.

Results: All PET indexes of [(18)F]FMISO significantly decreased after NAC. Although HV in primary tumor and a few indexes before NAC in responder was lower than that in nonresponder, none of the indexes were statistically significant.

Conclusions: Pretreatment [(18)F]FMISO could not predict NAC outcome in this study. However, [(18)F]FMISO uptake significantly decreased after NAC, and [(18)F]FMISO PET seemed to be a useful noninvasive tool for detecting hypoxia reduction after NAC.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Carcinoma, Squamous Cell / diagnostic imaging*
  • Carcinoma, Squamous Cell / drug therapy*
  • Female
  • Fluorine Radioisotopes / pharmacokinetics*
  • Head and Neck Neoplasms / diagnostic imaging*
  • Head and Neck Neoplasms / drug therapy*
  • Humans
  • Lymph Nodes / diagnostic imaging
  • Male
  • Middle Aged
  • Misonidazole / analogs & derivatives*
  • Misonidazole / pharmacokinetics
  • Neoadjuvant Therapy*
  • Positron-Emission Tomography
  • Treatment Outcome

Substances

  • Fluorine Radioisotopes
  • fluoromisonidazole
  • Misonidazole